RxDoctor Payments Data

Rick Faul, MD

Internal Medicine · Lafayette, LANPI 1861855371

Payments from drug & device makers

$774in general payments, 2019–2025

Across 44 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$202
  • Alkermes, Inc.$144
  • Amgen$84
  • Vanda Pharmaceuticals Inc.$42
  • Johnson & Johnson$38
  • Exact Sciences$34
  • plus $228 from 12 others

What the payments were for

  • Food & beverage$774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$774 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$21,951
Medicare patients
314
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide79$83,827
OzempicSemaglutide52$52,538
TrulicityDulaglutide34$50,975
EliquisApixaban57$49,621
JardianceEmpagliflozin46$35,208
XareltoRivaroxaban27$25,607
Lantus SolostarInsulin Glargine,hum.Rec.Anlog116$15,051
FarxigaDapagliflozin Propanediol20$12,537
LinzessLinaclotide18$9,545
Dexlansoprazole DrDexlansoprazole23$6,581
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$5,862
SymbicortBudesonide/Formoterol Fumarate17$5,484
Breo ElliptaFluticasone/Vilanterol15$5,386
Novolog FlexpenInsulin Aspart13$4,941
Gabapentin429$4,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$31$134,803113 claims
Boehringer IngelheimJardiance$18$35,20846 claims
Johnson & JohnsonXarelto$38$25,60727 claims
AbbVieLinzess$202$9,54518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →